For asymptomatic patients with Castrate-Resistant Prostate Cancer (CRPC), a window of opportunity is present. During this window of opportunity an intervention with little or no toxicity and the potential for extending the symptom-free period would be of great value to keep metastatic patients in an asymptomatic stage and thus delay the introduction of chemotherapy. The purpose of this study is to evaluate the safety and efficacy of ABR-215050 as an interventional agent for this role.~Overall survival for patients participating in study 07TASQ08 will be evaluated retrospectively using a separate study protocol 11TASQ11.
To investigate ABR-215050 as a possible treatment for prostate cancer.